On November 4^th, 2024, Zonhonbio officially initiated the Phase I clinical trial of its wholly original and globally independent intellectual property drug, ZHB103 Injection, at Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University).

As the sponsor, Zonhonbio's Phase I clinical study aims to evaluate the safety, tolerability, and pharmacokinetics of ZHB103 Injection in healthy volunteers.

With the goal of systematically developing humanized KKS system-based biopharmaceuticals, Zonhonbio is comprehensively exploring the potential therapeutic applications and drug development value of each component and its genetically engineered derivatives. Positioned as an innovative explorer in central nervous system (CNS) drugs, the company is committed to providing more effective treatment options for patients with CNS disorders.